Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure Biosciences' solid growth expected to continue, says SeeThruEquity

Reseach house SeeThruEquity issued an upbeat note on Pressure Biosciences following its first quarter results.
Pressure Biosciences' solid growth expected to continue, says SeeThruEquity

Reseach house SeeThruEquity issued an upbeat note on Pressure Biosciences Inc (OTCMKTS:PBIO) following its first quarter results.

The medtech and life sciences group began 2017 with nice growth, with revenues up 8% at $551,357 year-on-year, it said.

Business was particularly strong in the company's products and services segment, which demonstrated 16% annual growth led by strong instrument sales, noted SeeThruEquity.

"On its call with investors, PBIO management stated that it expected sales growth throughout the year as it expands distribution and selling partnerships, including the recently announced partnership with EKG Sales Associates; the company also expects an increase in grant revenues later in the year," it added.

A CE mark for Barocycler...

The research group also said that the firm had achieved its CE marking for its Barocycler 2320EXTREME sample instrument system faster than originally expected.

"The CE Marking is a significant milestone as it allows the Barocycler to be sold in Europe," it said.

"The company has announced that it is pursuing an uplisting to the Nasdaq, with a goal of completing the process by the end of 2Q17.

"We expect this move will require a transaction that will bring in much needed capital, but also affect shares outstanding, in order to meet minimum share price and shareholder's equity thresholds for a national listing," it added.

Last week, Joseph L. Damasio, chief financial officer, said: "As reported, we continued to show quarter-over-quarter revenue growth, especially in the important area of products and services.

"We also increased gross margins during the period. What makes these accomplishments even more rewarding was their achievement during a quarter in which we were also able to reduce operating expenses and operating loss."

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use